Former UCLA Decathlete Sentenced to 17.5 Years in Jail for Securities Fraud

Nov.22.2022
Former UCLA Decathlete Sentenced to 17.5 Years in Jail for Securities Fraud
Former UCLA decathlete sentenced to 210 months in prison for defrauding investors of over $45 million.

LOS ANGELES – A former decathlete from the University of California, Los Angeles who once competed for the Philippine national team was sentenced to 210 months in prison today for fraudulently raising over $45 million from investors. These investors were told their funds would be used to support a company marketing cannabis e-cigarettes.


David Joseph Bunevacz, 53 years old from the city of Calabasas, has been sentenced by US District Judge Dale S. Fischer to pay $35,267,851 in restitution. During today's sentencing hearing, Judge Fischer noted that Bunevacz had "bullied those who thought he was their friend," and that the severity of his actions cannot be measured solely in monetary terms.


Judge Fischer also found that even during the probationary period following his conviction in state court, Bunevacz continued to carry out his plan and concluded that "neither criminal conviction nor threat of imprisonment could persuade [Bunevacz] to become a law-abiding citizen.


On July 18th, Bunevacz admitted to committing securities fraud and telecommunications fraud. He has been in federal custody since his arrest on April 5th in connection to this case.


Going back to 2010, Bunevacz created various business entities, including CB Holding Group Corp. and Caesarbrutus LLC, which he claimed were involved in the marijuana industry and the sale of electronic cigarettes containing marijuana products such as CBD oil and THC.


Bunevacz reportedly lied to at least one investor about his supposed long-term partnership with a Chinese manufacturer of disposable e-cigarettes. According to court documents, he claimed to have obtained "pesticide-free raw material oil" that was sent to a laboratory for flavor infusion using a "proprietary custom process" to make vape flavoring smooth and discrete. He also provided fake documents such as bank statements, invoices, and purchase orders to support his claims of the company's success and need for investor funding.


Bunevacz did not use these funds to provide financial support for the operation of his business - despite the fact that some of his victims are currently experiencing serious financial difficulties. Instead, he diverted the vast majority of the funds to finance his own luxurious lifestyle, which includes a mansion in Calabasas, trips to Las Vegas, expensive jewelry and designer handbags, extravagant birthday parties for his daughter, and horses.


To create the appearance of conducting legitimate business activities for his company, Bunevacz registered various shell companies, including several with similar or identical names to legitimate marijuana businesses. To conceal his control over these shell companies and related bank accounts, Bunevacz listed other individuals, including his stepdaughter, as executives of the shell companies.


Bunevacz's blog praises his success as a former decathlete competing in the Philippines, and highlights appearances of his wife and daughter on a reality show. According to sworn statements submitted in support of the criminal prosecution, despite promoting his background, Bunevacz made efforts to conceal negative information from investors, such as his conviction for a felony in 2017 for illegally selling securities.


After an investor discovered a lawsuit against Bunevacz, the latter sent a forged version of a settlement agreement via email, claiming he had received $325,000 as part of the settlement. However, in reality, it was Bunevacz who agreed to pay $325,000 to settle the claim.


According to government records, Bunevacz raised approximately $45,227,266 from over 100 victim investors through his marijuana company. Judge Fischer found that Bunevacz caused approximately $35,267,851 in losses.


A prosecutor argued in a sentencing memorandum that "the violation of personal dignity, emotional harm, and lasting trauma caused by [Bunevacz] are reminiscent of the harm typically associated with violent crimes." "Furthermore, [Bunevacz] victimized over 100 individuals, causing harm on a scale rarely seen.


The Federal Bureau of Investigation, the Criminal Investigation Division of the Internal Revenue Service, and the Los Angeles County Sheriff's Department conducted an investigation into the matter. The Securities and Exchange Commission provided significant assistance. Assistant U.S. Attorney Alexander B. Schwab of the Major Frauds Section filed charges in this case.


Statement:


This article is based on third-party information that has been translated using machine translation, and is only intended for exchange and learning within the industry.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of its content. The translation of this article is only intended for industry communication and research purposes.


Due to limitations in the translation process, the translated article may not fully reflect the intended meaning of the original. Please refer to the original text for accuracy.


2FIRSTS maintains complete consistency with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.


The compilation of the information herein is copyrighted by the original media source and author. If infringement occurs, please contact us for prompt removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
During its coverage of Altria's booth at NACS Show 2026, 2Firsts documented product displays that prompted questions about U.S. tobacco advertising warning requirements. Following public comments from a former FDA official, 2Firsts sought responses from Altria and independently consulted U.S. regulatory lawyer Azim Chowdhury. Altria maintained that its B2B communications complied with applicable laws, while Chowdhury explained that federal warning rules provide no general trade-show exemption for e-cigarettes and nicotine pouches. The special report examines the broader regulatory implications.
Nov.04
Hungary Moves to End BAT-Backed Tobacco Supply Monopoly Eight Years Early After $200 Million in Profits, With No Compensation Planned
Hungary Moves to End BAT-Backed Tobacco Supply Monopoly Eight Years Early After $200 Million in Profits, With No Compensation Planned
Hungary's government announced on November 18, 2026, plans to terminate the exclusive tobacco retail supply concession held by Országos Dohányboltellátó (ODBE) on June 1, 2027, approximately eight years before the contract's scheduled expiry in 2035. ODBE is owned 49% by a Hungarian subsidiary of British American Tobacco (BAT) and 51% by Tabán Trafik. It has served as the exclusive supplier to Hungary's licensed tobacco retail network since 2015. The proposed legislation would end the concession without compensation and allow other qualified suppliers and tobacco wholesalers to serve retailers directly. ODBE generated HUF 67.3 billion (approximately $200 million) in after-tax profit between 2015 and 2025 and distributed nearly HUF 64 billion ($191 million) in dividends. The bill also proposes changes to retail margins, inventory rules, payment arrangements and procurement penalties, including those affecting heated tobacco products.
company
Nov.19 by 2Firsts Perspectives
Special Report|Virginia Vape Directory Shows Contrast Between Vuse and JUUL Pod Systems and CrossBar 20K, Loon Flavored Disposables
Special Report|Virginia Vape Directory Shows Contrast Between Vuse and JUUL Pod Systems and CrossBar 20K, Loon Flavored Disposables
A 2Firsts analysis of Virginia's liquid nicotine and vapor product certification directory identified 213 product records from 15 manufacturers. Companies associated with BAT, Altria, Imperial Brands, JTI and JUUL account for 127 entries. The directory also includes independent brands CrossBar 20K, Loon and Breeze. CrossBar advertises a 13mL disposable capable of up to 20,000 puffs, while Loon has 16 disposable entries featuring fruit, cooling and beverage-related flavors. Of all records, 120 are labeled as under FDA PMTA review. Virginia introduced revised penalties on October 1, 2026, including a minimum first-violation civil penalty of $5,000 per unlisted product, alongside new retail tobacco permitting requirements.
Regulations
Oct.30
Russia Expands Temporary Administration of JTI Assets in Second Round: From Four to All Seven Russian Entities, With Approximately $9.5 Billion in Related Assets
Russia Expands Temporary Administration of JTI Assets in Second Round: From Four to All Seven Russian Entities, With Approximately $9.5 Billion in Related Assets
Japan Tobacco Inc. (JT) confirmed on November 9, 2026, that all seven of its Russian entities had been placed under temporary administration after a second presidential decree added three companies to the four designated a day earlier. The additional entities are associated with importing, management, holdings and the former supply of Ploom heated-tobacco devices. JT disclosed approximately ¥1.5 trillion in Russian business-related assets as of September 30, including ¥360 billion in cash and deposits, and approximately ¥200 billion in liabilities. Under its revised FY2026 forecast, Russia accounts for about 25% of adjusted operating profit. JT said operations in Russia were continuing, while the financial impact remained under assessment.
company
Nov.09
Philip Morris Loses Two European Nicotine Pouch Patents in a Month Following BAT Challenges Over Nicotine Release and Formulation Technology
Philip Morris Loses Two European Nicotine Pouch Patents in a Month Following BAT Challenges Over Nicotine Release and Formulation Technology
The European Patent Office (EPO) published an appeal decision on November 17, 2026, revoking Philip Morris Products S.A.'s European nicotine pouch patent EP 3773494, covering a formulation involving free-base nicotine, ion-exchange resin and a water content of at least 15%. The decision followed an opposition and appeal brought by British American Tobacco (BAT) entity Nicoventures Trading Limited. Philip Morris withdrew its approval of the patent text during the appeal, leading the EPO to revoke the patent. A separate European patent, EP 3809884, covering the distribution of nicotine between a pouch membrane and its internal composition, had been revoked on September 24 following a challenge from another BAT entity. The patents share a 2019 priority basis, while related European divisional applications also exist.
company
Nov.18 by 2Firsts Perspectives
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Raja Krishnamoorthi on Oct. 6 questioned the FDA over its plan to reassess and potentially replace the 2021 PMTA regulatory framework, asking the agency to identify provisions it may change or eliminate, state whether current scientific evidentiary standards will be maintained, and disclose communications with Altria, Reynolds and other parties challenging the rule. Krishnamoorthi led a congressional investigation into JUUL and youth vaping in 2019 and has since remained active on e-cigarette regulation and enforcement.
Regulations
Oct.08